- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
eMed Technologies will refile IPO
Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange
Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange Commission. The Lexington, MA-based company pulled its IPO in November just as it was preparing to issue, citing a volatile market and investor apprehension about healthcare information systems vendors (SCAN 10/27/99).
eMed had hoped to raise more than $57 million through the IPO by selling 3.1 million shares at $12 to $14/share. The company anticipates the new IPO will be issued sometime during the first quarter of 2000, according to John Strauss, vice president of marketing. eMed also plans to use a different underwriter for this offering.
eMed is actively pursuing an Internet-based strategy that includes a new Web service for radiologists (eMed.net), and an extended relationship with compression software developer Aware to develop and market Web-based imaging products.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
